VANCOUVER, BC – January 13, 2023 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces today that IzoView will be featured on an upcoming segment of Advancements with Ted Danson (“Advancements”) via Amazon Prime Video and Bloomberg TV. The Company will update shareholders when filming for the segment commences on social media, and will disclose the airing date and time in a formal news release when determined.
The news release issued by Advancements follows:
“An upcoming Segment of Advancements will Explore the Future of Breast Imaging
Learn how developments in technology are improving the outcomes of breast cancer.
Jupiter, FL—An upcoming segment of Advancements with Ted Danson will focus on innovations in CT imaging tools and technologies.
In this episode, viewers will learn about the increasing rates of breast cancer, which in recent years has surpassed lung cancer as the most common form. Audiences will learn how developments in CT imaging technology are providing more accurate detection and diagnosis of breast cancers.
Viewers will learn about Izotropic Corporation’s IzoView Breast CT imaging platform, which produces high resolution breast images in true 3D with low radiation dose levels.
“IzoView has the potential to revolutionize breast imaging as we know it”, said Dr. John McGraw, Chief Executive Officer of Izotropic. “We’re preparing for a clinical study initiating this year for market authorization in the USA to bring our breast CT technology to hospitals and clinics across the country. IzoView will offer a whole new experience for patients, providers, radiologists, and other surgical and oncology specialists. We’re very proud of our technology and the impact we intend to have on breast cancer diagnostics to improve the outcomes of breast cancer .”
In addition, the show will discover what makes the platform ideal for imaging patients with dense breast tissue.
“One 10 second scan acquires approximately 500 images. The process is quick and removes the need for painful breast compression or continual technician breast handling, providing a more comfortable patient experience,” said Ed Sullivan, senior producer for the Advancements series. “We look forward to sharing this information with viewers.”
About Izotropic:
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
For more information, visit https://izocorp.com/
About Advancements and DMG Productions:
Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.
Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.
For more information, please visit www.AdvancementsTV.com or call 866-496-4065.”
ON BEHALF OF THE BOARD
Investor Relations Contact:
Mr. James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.